Parabilis Medicines, Inc. (PBLS)
$26.85-7.25%Close
SELL
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $88M
- Beta
- 5.03
- P/E (TTM)
- -0.73
- Short % float
- 272.23%
- Days to cover
- 4.8
- SI change
- +35.6%
- 1W
- -6.96%
- 1M
- -25.75%
- vs SPY 1W
- -6.83%
- vs SPY 1M
- -28.25%
Industry peers
FMP comparable companies · ranked by market cap
- RLAYSELLRelay Therapeutics, Inc.$3.8BRECOVERYQ 2$17.41-3.45%
- TNGXSELLTango Therapeutics, Inc.$3.7BRECOVERYQ 23$22.57-8.07%
- ZYMESELLZymeworks Inc.$1.9BBEARQ 12$25.26-1.03%
- IMNMSELLImmunome, Inc.$1.8BCRISISQ 17$19.31-8.20%
- CGEMSELLCullinan Therapeutics, Inc.$950MCRISISQ 1$15.46-5.69%
- GLUESELLMonte Rosa Therapeutics, Inc.$872MCRISISQ 7$10.32-5.99%
- CTMXSELLCytomX Therapeutics, Inc.$538MCRISISQ 6$2.47-3.72%
- CBIOSELLCrescent Biopharma, Inc.$524MCRISISQ -2$14.12-10.72%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on PBLS?
- LOPJLB’s latest quantitative signal on Parabilis Medicines, Inc. (PBLS) is SELL. Signals are updated daily.
- What market regime is PBLS in?
- LOPJLB classifies each ticker into BULL, RECOVERY, BEAR, or CRISIS regimes using a Hidden Markov Model.
- What does Parabilis Medicines, Inc. (PBLS) do?
- Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 and is headquartered in Cambridge, MA.